Emergent Biosolutions (NYSE:EBS) Releases Quarterly Earnings Results, Beats Expectations By $0.68 EPS

Emergent Biosolutions (NYSE:EBS) released its earnings results on Wednesday. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.68, FiscalAI reports. The company had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%.

Here are the key takeaways from Emergent Biosolutions’ conference call:

• Q2 results exceeded expectations, with revenue of $234 million and adjusted EBITDA of $97 million, up from $33 million a year earlier. Medical countermeasure deliveries to U.S. government customers were accelerated, driving much of the outperformance.
• The medical countermeasures business remains a key growth driver, with Q2 revenue of $168 million and new contract modifications totaling $117.2 million for ACAM2000 and botulism antitoxin. International MCM sales represented about 20% of first-half MCM revenue.
• Emergent lowered 2026 revenue guidance to $645 million-$675 million from $720 million-$760 million and reduced adjusted EBITDA guidance to $130 million-$150 million, citing increased competition, pricing pressure, and volume pressure in the naloxone market.
• The company recorded a $191 million non-cash impairment charge against its NARCAN asset group and expects further price erosion as new nasal naloxone competitors enter the market. Emergent said total naloxone unit demand may remain roughly flat while it works to defend its more-than-50% market share.
• Emergent is restructuring to generate approximately $40 million in annualized savings, including about 90 job reductions, facility closures, and other footprint changes; most savings are expected to be realized in 2027. Liquidity also improved through accounts-receivable collections, debt refinancing, and lower gross debt.

Emergent Biosolutions Stock Performance

NYSE EBS traded down $0.01 during trading hours on Wednesday, hitting $7.55. The company had a trading volume of 707,748 shares, compared to its average volume of 659,451. Emergent Biosolutions has a fifty-two week low of $6.03 and a fifty-two week high of $14.06. The company has a quick ratio of 2.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.10. The business has a fifty day simple moving average of $7.98 and a 200-day simple moving average of $8.83. The firm has a market cap of $389.84 million, a P/E ratio of -26.98 and a beta of 2.35.

Wall Street Analysts Forecast Growth

EBS has been the subject of a number of research reports. UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Weiss Ratings lowered shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Finally, Benchmark restated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Emergent Biosolutions has a consensus rating of “Hold” and an average target price of $12.00.

Insider Activity

In other news, SVP Paul Anthony Williams sold 3,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the transaction, the senior vice president owned 159,098 shares of the company’s stock, valued at approximately $1,336,423.20. The trade was a 1.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.00% of the company’s stock.

Institutional Trading of Emergent Biosolutions

Several hedge funds have recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co acquired a new position in Emergent Biosolutions during the 4th quarter valued at about $45,000. Legal & General Group Plc acquired a new position in shares of Emergent Biosolutions during the second quarter valued at $31,000. Raymond James Financial Inc. acquired a new stake in Emergent Biosolutions in the second quarter worth about $53,000. Kemnay Advisory Services Inc. bought a new position in Emergent Biosolutions in the 4th quarter valued at about $107,000. Finally, Abel Hall LLC acquired a new position in Emergent Biosolutions during the 4th quarter valued at about $129,000. 78.40% of the stock is currently owned by institutional investors.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.